Search results for Gsk

<![CDATA[GSK Enters Exclusive Collaboration with SBP Group to Accelerate Bepirovirsen at Launch in Mainland China ]]&...

GSK plc (GSK) Discusses Bepirovirsen Phase III Data and Advances in Hepatitis B Treatment Transcript

GSK CEO's 'scientific courage' propels plans for medley of phase 3 trials for Hansoh-partnered ADC

When Fierce last caught up with GSK’s head of oncology R&D back in November, we were told to “stay tuned” for the pharma to publish its own hotly anticipated data on a pair of...

GSK walks away from $100M bet on Mersana's STING ADC, pauses mRNA bird flu shot program

GSK has finally called time on its pact with Mersana Therapeutics despite sinking $100 million to secure an option for an antibody-drug conjugate (ADC).

GSK: Improved Prospects After Correction

<![CDATA[Pharmaceutical Executive Daily: GSK Enters Collaboration to Support Launch of Bepirovirsen]]>

Which blockbuster is GSK gunning for next? CEO Miels is looking to oncology

When it comes to GSK’s new dealmaking strategy of trying to outdo established blockbusters, CEO Luke Miels has told Fierce that oncology may offer the most tempting targets.

GSK reports promising early results in ovarian and womb cancer drug trial

Mo-Rez reduced or eliminated tumours in over 60% of patients and is expected to be a blockbuster drugGSK has revealed positive results for a treatment for gynaecological cancers as...

GSK cuts deal with Sino to broaden reach of hepatitis B drug

The marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and could speed access to a therapy called bepirovirsen that’s important to...

GSK sees blockbuster potential in targeted cancer therapy after promising early data

GSK pens $1B deal with China’s SiranBio for oligonucleotide that could reduce abdominal fat

GSK has found another potential way to treat cardiometabolic disease with a modality close to the pharma’s heart—oligonucleotides.

Why is everyone buying GSK shares?

GSK shares have been outperforming the FTSE 100 in 2026. Paul Summers takes a closer look and asks whether this might continue. The post Why is everyone buying GSK shares? appeared...

GSK’s $700M Alector bet blows up as Alzheimer’s drug flunks phase 2

GSK and Alector have stopped a phase 2 trial of their Alzheimer’s disease drug candidate after an interim analysis found the study was unlikely to hit its primary endpoint.

As GSK shares fall 5% on Q1 news, is this a buying opportunity?

GSK reinforced its upbeat guidance for the year ahead in a Q1 update, after an impressive 2025, but the shares fell back in response. The post As GSK shares fall 5% on Q1 news, is...

Cancer drug demand helps AstraZeneca and GSK boost their bottom lines

Pharmaceutical drug giants AstraZeneca and GSK both saw cancer drug sales rise in their latest quarter.

Galapagos NV (GLPG) Signs Agreement with Gilead on Ouro Medicines Assets

GSK’s hepatitis B drug cures one-fifth of patients in ‘major step’ for pervasive disease

GSK is pulling back the curtain on the phase 3 success of its chronic hepatitis B drug bepirovirsen, revealing that nearly one-fifth of all treated patients across two trials were...

Suddenly investors can’t get enough of GSK shares! What’s going on?

After years in the doldrums, GSK shares are suddenly the most bought stock on the entire FTSE 100. Harvey Jones thinks he knows why. The post Suddenly investors can’t get enough of...

GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’

The findings supporting bepirovirsen were deemed a “historic moment” by physicians and validate a drug that has “clear blockbuster potential,” according to one analyst.

Gilead Sciences: Why I'm Tempted To Sell Ahead Of Q1 Earnings - But Won't

<![CDATA[Gilead Enters $5 Billion Agreement to Acquire Tubulis ]]>

Judge Knocks Out Pfizer Partner's Vax Case Against GSK

A Delaware federal judge on Thursday threw out a suit seeking a finding that a drug developer that partnered with Pfizer and BioNTech on their COVID-19 vaccine didn't infringe drug...

GSK, Moderna Both Ordered To Provide More Info In Vax Fight

A special master overseeing discovery disputes in GlaxoSmithKline's infringement suits over Moderna's COVID-19 and related respiratory syncytial virus vaccines ordered both compani...

<![CDATA[Pharma M&A Roundup: Gilead Sciences Expands Collaboration with World Health Organization, Johnson &...